A clinical-stage biotech firm delivering next-generation cell therapies and immuno-oncology solutions to the global oncology market with record-breaking 2024 revenue growth.
CTMX offers exposure to the high-growth cell therapy sector with a proven track record of revenue expansion from $53.2M in 2022 to $138.1M in 2024. The company's ability to generate net income for the first time while maintaining a growing pipeline suggests de-risking milestones are being met efficiently. Strategic partnerships provide recurring revenue visibility and reduce reliance on costly standalone commercialization efforts.
Despite recent profitability, the company's negative shareholders' equity of -$456,000 and total liabilities of $121.0M indicate precarious financial leverage that could restrict future growth options. High operating expenses relative to revenue growth suggest burn rates may remain elevated if clinical outcomes do not accelerate as planned. The biotech sector is highly volatile, and any adverse trial data or regulatory delays could cause severe stock depreciation regardless of current earnings.
CytomX Therapeutics (CTMX) is a clinical-stage biotechnology company focused on developing novel cell therapies and immuno-oncology solutions. The company serves the global oncology market with proprietary technologies aimed at enhancing immune system responses against cancer. Recent financials highlight a significant revenue jump to $138.1M in 2024, driven by successful product launches and strategic partnerships.
Management has successfully executed a turnaround strategy, evidenced by the shift from a $-99.3M loss in 2022 to a $31.9M net profit in 2024. While operating expenses of $113.1M remain high due to R&D investments ($83.4M), the company achieved positive cash flow from operations adjustments and secured substantial financing inflows of $7.5M. The balance sheet remains fragile with shareholders' equity near zero, indicating a need for continued strategic capital management.
The global cell therapy market is projected to exceed $100B by 2030, driven by advancements in CAR-T and gene-edited therapies for cancer and autoimmune diseases. Competitors like Kite Pharma and Bluebird Bio dominate the space, but emerging players with differentiated platforms like CTMX are gaining traction through licensing deals. Regulatory pathways continue to evolve, offering opportunities for first-in-class products that can command premium pricing.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $53.2M | $101.2M | $138.1M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $53.2M | $101.2M | $138.1M |
| Operating Expenses | $154.5M | $107.7M | $113.1M |
| Operating Income | $-101.3M | $-6.5M | $25.0M |
| R&D | $111.6M | $77.7M | $83.4M |
| G&A | $42.8M | $30.0M | $29.7M |
| Stock-Based Comp | $13.1M | $8.6M | $7.7M |
| Depreciation | $2.3M | $2.0M | $1.6M |
| Amortization | $146.0K | $146.0K | $146.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $2.0M | $9.8M | $7.1M |
| Interest Income | $1.7M | $9.8M | $7.1M |
| Pre-Tax Income | $-99.3M | $3.3M | $32.1M |
| Income Tax | $0 | $3.9M | $224.0K |
| Continuing Ops | $-99.3M | $-569.0K | $31.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-99.3M | $-569.0K | $31.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-99.3M | $-569.0K | $31.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $237.1M | $182.9M | $107.3M |
| Cash & Equivalents | $193.7M | $17.2M | $38.1M |
| Accounts Receivable | $36.0M | $3.4M | $3.1M |
| Prepaid Expenses | $7.5M | $5.0M | $3.6M |
| Other Current Assets | $0 | $157.3M | $62.6M |
| Long-Term Assets | $23.8M | $18.9M | $13.2M |
| PP&E (Net) | $5.1M | $4.0M | $2.5M |
| Goodwill | $949.0K | $949.0K | $949.0K |
| Operating Leases | $15.9M | $12.2M | $8.1M |
| Other LT Assets | $1.8M | $1.7M | $1.7M |
| Total Assets | $260.9M | $201.8M | $120.5M |
| Current Liabilities | $152.6M | $155.9M | $85.8M |
| Accounts Payable | $2.8M | $1.5M | $1.1M |
| Current Leases | $4.1M | $4.6M | $5.1M |
| Deferred Revenue | $121.3M | $132.3M | $67.2M |
| Other Current Liab | $-4.1M | $0 | $0 |
| Long-Term Liabilities | $194.0M | $93.3M | $35.2M |
| LT Operating Leases | $14.0M | $9.4M | $4.2M |
| Other LT Liab | $0 | $3.9M | $4.1M |
| Total Liabilities | $346.6M | $249.2M | $121.0M |
| Shareholders' Equity | $-85.8M | $-47.4M | $-456.0K |
| Paid-In Capital | $637.1M | $675.9M | $691.1M |
| Retained Earnings | $-722.9M | $-723.4M | $-691.6M |
| AOCI | $10.0K | $95.0K | $27.0K |
| Total L&E | $260.9M | $201.8M | $120.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-99.3M | $-569.0K | $31.9M |
| Non-Cash Adjustments | $-65.6M | $69.9M | $2.2M |
| Working Capital Changes | $54.1M | $-125.4M | $-120.3M |
| Cash from Operations | $-110.8M | $-56.0M | $-86.2M |
| Capital Expenditures | $1.7M | $840.0K | $310.0K |
| Cash from Investing | $98.3M | $-150.7M | $99.7M |
| Cash from Financing | $648.0K | $30.2M | $7.5M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-11.9M | $-176.5M | $21.0M |
| Beginning Cash | $206.4M | $194.6M | $18.1M |
| Ending Cash | $194.6M | $18.1M | $39.1M |
The company's revenue is primarily generated from its proprietary cell therapy platform, which includes licensed products like CTX001 for cancer treatment. Additional streams include collaboration fees and royalties from strategic partnerships within the immuno-oncology sector. The firm also derives income from government grants and research funding supporting its preclinical and clinical development programs.
As a clinical-stage biotech, CTMX faces the high risk of failure in ongoing or future clinical trials which could wipe out its pipeline value. The company carries significant debt obligations with total liabilities exceeding assets ($121.0M vs $120.5M), raising solvency concerns despite recent cash inflows. Regulatory approval timelines for novel cell therapies are uncertain and subject to FDA scrutiny. Revenue concentration in a single product or partnership could expose the stock to volatility if key agreements lapse.
CTMX leverages a proprietary gene-editing platform that enables rapid, cost-effective manufacturing of personalized cell therapies. Its extensive pipeline of early-stage assets offers multiple potential blockbuster candidates with high unmet medical need in oncology. Strong cash flow generation in 2024 ($31.9M net profit) provides financial flexibility to fund R&D without immediate dilution.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.